Jasper Therapeutics (JSPR) Announces Additional Positive Data from Phase 1b/2a of briquilimab Mar 15, 2024 08:01AM
Jasper Therapeutics (JSPR) Presents Positive Final Results from Phase 1 Study of Briquilimab in Patients with AML or MDS Dec 11, 2023 03:55AM
Jasper Therapeutics (JSPR) Appoints Stephen J. Galli to its Board May 10, 2023 08:02AM
Jasper Therapeutics (JSPR) Announces Positive Follow-up Clinical Data from Investigator-Sponsored Study of Briquilimab Conditioning in Fanconi Anemia Patients at the 2023 Transplantation & Cellular Th Feb 17, 2023 08:11AM
Jasper Therapeutics (JSPR) Announces New Positive Briquilimab Data to be Presented at the 2023 Tandem Meetings Jan 13, 2023 08:02AM


Sep 26, 2022 08:02AM Jasper Therapeutics (JSPR) Announces Positive Clinical Data from Study of JSP191
Apr 26, 2022 04:05PM Jasper Therapeutics (JSPR) Reports Updated Data from Phase 1 Clinical Trial of JSP191
Mar 21, 2022 08:32AM Jasper Therapeutics (JSPR) Announces Management Changes to Strengthen Leadership Team